Martin Dreyling
Professor of Medicine
Department of Medicine III, LMU University Hospital · Munich, Germany
Chair of the European MCL Network. Has led pivotal European trials defining the standard of care for MCL across age groups. Co-author of ESMO guidelines for MCL management.
Modern Management of Mantle Cell Lymphoma.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · Jun 1, 2026
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.
Lancet (London, England) · May 16, 2026
Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)-MCL0208 clinical trial.
HemaSphere · May 1, 2026
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3.
Blood · Mar 19, 2026
Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.
Leukemia · Jan 1, 2026
A matching-adjusted indirect comparison of survival outcomes with pirtobrutinib (BRUIN) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor.
British journal of haematology · Jan 1, 2026
Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020.
Haematologica · Oct 30, 2025
EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma.
HemaSphere · Oct 1, 2025
The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatment.
BMC cancer · Aug 25, 2025
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Jul 10, 2025
Prognostic biomarkers in MCL: insights from the SHINE trial on the impact of MCL35 score and TP53 mutation status.
Blood · Jun 19, 2025
First Line Therapy in Mantle Cell Lymphoma-The Role of BTKi in the Initial Treatment of Transplant-Eligible and -Ineligible Patients.
Hematological oncology · Jun 1, 2025
BR or R-CHOP induction with rituximab maintenance in untreated, transplant-ineligible patients with mantle cell lymphoma.
Blood advances · May 13, 2025
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study.
Blood cancer journal · Apr 24, 2025
Treatment of relapsed/refractory MCL.
Blood · Feb 13, 2025
Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network.
British journal of haematology · Jan 1, 2025
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL.
Hematology. American Society of Hematology. Education Program · Dec 6, 2024
Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials.
Leukemia · Dec 1, 2024
Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis.
Leukemia & lymphoma · Nov 1, 2024
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
Blood · Aug 22, 2024
Knowledge, skills, and confidence gaps impacting treatment decision making in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma: a quantitative survey study in France, Germany, and the United States.
BMC cancer · Aug 13, 2024
Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma.
Blood advances · Jul 23, 2024
Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group.
Annals of hematology · Jul 1, 2024
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.
Leukemia · Jun 1, 2024
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
Lancet (London, England) · May 25, 2024
Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Feb 10, 2024
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma.
Leukemia & lymphoma · Jan 1, 2024